Notably, circFOXK2 knockdown resulted in decreased complex IV activity, OCR, mtROS, stemness, SOX2 expression, and enhanced sensitivity to cisplatin in T24‐CIS cells (Figure S7K–R, Supporting Information). The gene discussed is SOX2; the disease is in situ carcinoma.